Journal of Carcinogenesis & Mutagenesis

Abstract

Trends in Focal Nodular Hyperplasia of the Liver along with Oxaliplatin-Induced this Entity

Kazumi Fujioka*

It is known that Focal Nodular Hyperplasia (FNH) of the liver is the second common benign liver tumor following hemangioma. Recently, it is Probable that the Senescence-Associated Secretory Phenotype (SASP) plays a crucial role for fibrosis, inflammation, and reduced apoptotic cell death, leading to the increased tissue volume observed in FNH. Regarding microRNAs (miRNA), the results provided that the decreased miR-18a, miR-195, and miR-210 expressions may differentiate FNH from cirrhosis suggesting the different pathogenesis of two entities. In this article, current knowledge and trends of FNH along with oxaliplatin-induced this entity have been reviewed in detail. Additionally, the author described previously treated two cases of FNH showing peculiar image features and clinical presentation. Results provided that unique endothelial cell expressed SOST of fibrous septa in FNH with no therapy contributes to promote the fibrosis process through Platelet-Derived Growth Factor β/ Platelet-Derived Growth Factor Receptor β (PDGFB/PDGFRB) pathway using the integrated analysis. Further investigations are needed to elucidate the unique natures, especially in endothelial cell of fibrous septa in FNH. As it is known that FNH lesions also develop after treatment using oxaliplatin in adult population, the accurate diagnosis in FNH using comprehensive image modalities such as MRI and Contrast-Enhanced Ultrasonography (CEUS), along with the consideration of the interval between the completion of oxaliplatin therapy and the detection of new lesion may avoid unnecessary surgery.

Published Date: 2023-03-20; Received Date: 2023-02-17